Pharsight

Drugs that contain Pitolisant Hydrochloride

1. Wakix patents expiration

WAKIX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7169928 HARMONY Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications
Feb, 2020

(4 years ago)

US8207197 HARMONY Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine
Mar, 2030

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7910605 HARMONY Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications
Sep, 2022

(1 year, 7 months ago)

US8354430 HARMONY Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine
Feb, 2026

(1 year, 8 months from now)

US8486947 HARMONY Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands
Sep, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 14, 2024
Orphan Drug Exclusivity(ODE-255) Aug 14, 2026
Orphan Drug Exclusivity(ODE-331) Oct 13, 2027
New Indication(I-846) Oct 13, 2023

NCE-1 date: 15 August, 2023

Market Authorisation Date: 14 August, 2019

Treatment: Method of treating cataplexy in patients with narcolepsy

Dosage: TABLET;ORAL

More Information on Dosage

WAKIX family patents

Family Patents